Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab.

Bruera G, Cannita K, Giuliante F, Lanfiuti Baldi P, Vicentini R, Marchetti P, Nuzzo G, Antonucci A, Ficorella C, Ricevuto E.

Clin Colorectal Cancer. 2012 Jun;11(2):119-26. doi: 10.1016/j.clcc.2011.11.002. Epub 2011 Dec 27.

PMID:
22206922
2.

Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease.

Bruera G, Cannita K, Di Giacomo D, Lamy A, Troncone G, Dal Mas A, Coletti G, Frébourg T, Sabourin JC, Tosi M, Ficorella C, Ricevuto E.

BMC Med. 2012 Nov 8;10:135. doi: 10.1186/1741-7015-10-135.

3.

Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype.

Bruera G, Cannita K, Giordano AV, Vicentini R, Ficorella C, Ricevuto E.

Int J Oncol. 2014 Jan;44(1):17-26. doi: 10.3892/ijo.2013.2179. Epub 2013 Nov 15.

4.

"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study.

Bruera G, Santomaggio A, Cannita K, Baldi PL, Tudini M, De Galitiis F, Mancini M, Marchetti P, Antonucci A, Ficorella C, Ricevuto E.

BMC Cancer. 2010 Oct 19;10:567. doi: 10.1186/1471-2407-10-567.

5.

Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx).

Bruera G, Cannita K, Di Giacomo D, Lamy A, Frébourg T, Sabourin JC, Tosi M, Alesse E, Ficorella C, Ricevuto E.

BMC Med. 2013 Mar 4;11:59. doi: 10.1186/1741-7015-11-59.

6.

Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.

DʼAngelica MI, Correa-Gallego C, Paty PB, Cercek A, Gewirtz AN, Chou JF, Capanu M, Kingham TP, Fong Y, DeMatteo RP, Allen PJ, Jarnagin WR, Kemeny N.

Ann Surg. 2015 Feb;261(2):353-60. doi: 10.1097/SLA.0000000000000614.

7.

Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels.

Kim S, Dobi E, Jary M, Monnien F, Curtit E, Nguyen T, Lakkis Z, Heyd B, Fratte S, Cléau D, Lamfichekh N, Nerich V, Guiu B, Demarchi M, Borg C.

BMC Cancer. 2013 Dec 27;13:611. doi: 10.1186/1471-2407-13-611.

8.

Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.

Gruenberger T, Bridgewater J, Chau I, García Alfonso P, Rivoire M, Mudan S, Lasserre S, Hermann F, Waterkamp D, Adam R.

Ann Oncol. 2015 Apr;26(4):702-8. doi: 10.1093/annonc/mdu580. Epub 2014 Dec 23.

PMID:
25538173
9.

Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen.

Bruera G, Cannita K, Giordano AV, Vicentini R, Ficorella C, Ricevuto E.

Int J Oncol. 2014 Jun;44(6):1820-30. doi: 10.3892/ijo.2014.2369. Epub 2014 Apr 4.

10.

[Preoperative chemotherapy in the surgical treatment of colorectal liver metastases].

Dede K, Láng I, Pörneczi B, Mester G, Fekete A, Kőszegi G, Mersich T, Besznyák I, Bursics A.

Magy Seb. 2013 Dec;66(6):325-30. doi: 10.1556/MaSeb.66.2013.6.4. Hungarian.

PMID:
24333977
11.

Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection.

Constantinidou A, Cunningham D, Shurmahi F, Asghar U, Barbachano Y, Khan A, Mudan S, Rao S, Chau I.

Clin Colorectal Cancer. 2013 Mar;12(1):15-22. doi: 10.1016/j.clcc.2012.07.002. Epub 2012 Sep 26.

PMID:
23021126
12.

Standardized added metabolic activity (SAM) IN ¹⁸F-FDG PET assessment of treatment response in colorectal liver metastases.

Mertens J, De Bruyne S, Van Damme N, Smeets P, Ceelen W, Troisi R, Laurent S, Geboes K, Peeters M, Goethals I, Van de Wiele C.

Eur J Nucl Med Mol Imaging. 2013 Aug;40(8):1214-22. doi: 10.1007/s00259-013-2421-z. Epub 2013 May 1.

PMID:
23636802
13.

Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer.

Degirmenci M, Karaca B, Gorumlu G, Durusoy R, Demir Piskin G, Bozkurt MT, Cirak Y, Tunali D, Karabulut B, Sanli UA, Uslu R.

Med Oncol. 2010 Sep;27(3):585-91. doi: 10.1007/s12032-009-9253-5. Epub 2009 Jun 13. Review.

PMID:
19526201
14.

Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.

Bennouna J, Borg C, Delord JP, Husseini F, Trillet-Lenoir V, Faroux R, François E, Ychou M, Goldwasser F, Bouché O, Senellart H, Kraemer S, Douillard JY.

Clin Colorectal Cancer. 2012 Mar;11(1):38-44. doi: 10.1016/j.clcc.2011.05.002. Epub 2011 Jul 29.

PMID:
21803002
15.

Effectiveness and safety of intensive triplet chemotherapy plus bevacizumab, FIr-B/FOx, in young-elderly metastatic colorectal cancer patients.

Bruera G, Cannita K, Giordano AV, Vicentini R, Ficorella C, Ricevuto E.

Biomed Res Int. 2013;2013:143273. doi: 10.1155/2013/143273. Epub 2013 Nov 6.

16.

Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resection.

Ghiringhelli F, Bichard D, Limat S, Lorgis V, Vincent J, Borg C, Berthou J, Orry D, Ortega-Deballon P, Lakkis Z, Facy O, Heyd B, Rat P, Nerich V, Ladoire S.

Ann Surg Oncol. 2014 May;21(5):1632-40. doi: 10.1245/s10434-013-3463-y. Epub 2014 Jan 14.

17.

Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA Cohort.

Rouyer M, Smith D, Laurent C, Becouarn Y, Guimbaud R, Michel P, Tubiana-Mathieu N, Balestra A, Jové J, Robinson P, Noize P, Moore N, Ravaud A, Fourrier-Réglat A; ETNA study group.

Target Oncol. 2016 Feb;11(1):83-92. doi: 10.1007/s11523-015-0377-6.

PMID:
26298481
18.

Successful combination therapy of radical liver resection with 5-fluorouracil/leucovorin, oxaliplatin, plus bevacizumab for ascending colon cancer with pulmonary and 43 liver metastases: report of a case.

Ochiai T, Masuda T, Yagi M, Kasai R, Furuyama T, Tsukamoto K, Ito H, Igari K, Aihara A, Kumagai Y, Iida M, Odajima H, Tanaka S, Arii S, Yamazaki S.

Int Surg. 2012 Jan-Mar;97(1):6-13. doi: 10.9738/CC88.1.

19.

[Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC].

Guo X, Liu TS, Yu YY, Zhou YH, Chen Y, Zhuang RY, Cui YH.

Zhonghua Zhong Liu Za Zhi. 2013 Aug;35(8):604-7. Chinese.

PMID:
24314219
20.

The 'real-life' impact of adding bevacizumab to first-line therapy in metastatic colorectal cancer patients: a large Israeli retrospective cohort study.

Hammerman A, Greenberg-Dotan S, Battat E, Feldhamer I, Bitterman H, Brenner B.

Acta Oncol. 2015 Feb;54(2):164-70. doi: 10.3109/0284186X.2014.958532. Epub 2014 Oct 28.

PMID:
25350524

Supplemental Content

Support Center